Navigation Links
Additional Data from the Qnexa Phase 3 Studies Presented at The Obesity Society 27th Annual Scientific Meeting
Date:10/29/2009

the overall percent weight loss in the EQUIP study was 11% for patients on full dose Qnexa, as compared to 1.6% for the placebo group."

Also included in the presentation were discontinuation rates for cognitive events. Overall, these rates were low and the events were generally mild to moderate and reversible with discontinuation of treatment. There was one severe event in the treatment arm and one in the placebo arm that led to discontinuation. Specifically, the discontinuation rates for various cognitive-related events were as follows:


    % of Patients             EQUIP (n=1,264)           CONQUER (n=2,485)
    -------------       ------------------------    -------------------------
    MedDRA Preferred               Qnexa   Qnexa               Qnexa    Qnexa
     Terms              Placebo     Low     Full    Placebo     Mid     Full
    ----------------    -------    -----   -----    -------    -----    -----
    Disturbance in
     Attention             0.4%     0.0%     1.4%      0.1%     0.0%     0.7%
    Memory Impairment      0.0%     0.0%     0.0%      0.1%     0.0%     0.5%
    Amnesia
     (forgetfulness)       0.2%     0.0%     0.6%      0.0%     0.2%     0.3%
    Aphasia (word
     finding
     difficulties)         0.0%     0.0%     0.2%      0.0%     0.0%     0.3%
    Cognitive Disorder     0.2%     0.0%     0.0%      0.0%     0.0%     0.2%
    Confusional State      0.0%     0.4%     0.2%      0.1%     0.2%     0.1%
    Bradyphrenia
     (slow thinking)       0.0%     0.0%     0.2%      0.0%     0.0%     0.0%
    Disorientation         0.0%     0.0%     0.0%      0.0%     0.0%     0.0%
    Mental Impairment      0.0%     0.0%     0.0%      0.0%     0.0%     0.0%

    Events are not additive as some patients have reported more than one event
    leading to study drug discontinuation.

Consistent with standard scientific and regulatory methodologies, these infrequent events that lead to study drug discontinuati
'/>"/>

SOURCE VIVUS, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
2. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
3. First Osteoporosis Study in Hip Fracture Patients Finds Once-Yearly Reclast(R) Prevents Additional Fractures and Improves Survival
4. PTC Therapeutics Announces Additional Results from Phase 2 Study of PTC124 in Duchenne Muscular Dystrophy
5. Bayer Issues Additional Guidance to Physicians on Trasylol(R)
6. Coley Pharmaceutical Group and Pfizer Nominate Additional Anti-Cancer Compound for Clinical Development
7. Progen Presents Additional Analysis of Data from PI-88 Phase 2 Liver Cancer Study at American Association for the Study of Liver Diseases
8. Pharmacopeia Announces Additional Positive Findings from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA)
9. Sulodexide Data Safety Monitoring Committee Completes Additional Review of Phase 3 Study Data
10. Indevus Reports Additional Positive Phase III Trial Data for NEBIDO(R)
11. Paul Capital Healthcare Purchases Additional Royalty Interest in GlaxoSmithKlines Rotarix(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)...  Zafgen, Inc., a leading biopharmaceutical company dedicated to ... today announced initial results from its Phase 2a ... aminopeptidase 2 (MetAP2), in patients with Prader-Willi syndrome ... results showed improvements in body weight, hunger-related behaviors, ...
(Date:1/14/2014)... , Jan. 14, 2014 The Brandeis Medical Center, led by ... a premier and affordable laser tattoo removal experience with the ... focus is in providing high quality cosmetic services with cutting edge ... " Southern California has seen a dramatic ...
(Date:1/14/2014)... CLEVELAND , Jan. 14, 2014 NineSigma ... will hold its Innovation Leadership Summit , May ... in Cleveland Ohio . ... innovators and organizations committed to breakthrough achievements through open ...
Breaking Medicine Technology:Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 2Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 3Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 4
... 2011  Thoratec (NASDAQ: THOR), a world leader in device-based ... failing hearts, said today it will be participating in ... Tuesday, December 13. Taylor C. Harris, Senior ... an update on the company, beginning at 10:15 a.m., ...
...  VolitionRX Limited (VNRX.OB), a life sciences company focused on ... it will issue US$1,110,000 worth of shares of its ... issuance is the final requirement of the Share Purchase ... June 2011) between ValiRx and Singapore Volition Pte Limited, ...
Cached Medicine Technology:VolitionRX Limited Issues 525,000 Shares to ValiRx; Final Requirement of Share Purchase Agreement 2
(Date:4/18/2014)... Johns Hopkins University School of Medicine researchers have been ... for diabetes, Novo Nordisk announced this month. Of the ... and Obesity Biologics Science Forum Program, only four projects ... Hopkins researchers. They are Jonathan Powell, M.D., Ph.D.; G. ... , Jonathan Powell, a professor of oncology, will use ...
(Date:4/18/2014)... WA April 18, 2014) Benaroya Research Institute ... research how blocking a particular molecule in metastatic breast ... the number of lung metastases. BRI scientists have found ... can shrink tumors by 60 - 80 percent and ... the lung. The $1.8 million five-year grant comes from ...
(Date:4/18/2014)... San Diego, Calif. (April 18, 2014) ― A new ... analyzing weekly patterns in health-related Google searches reveals ... public health strategies. , Investigators from San ... University, and the Monday Campaigns, analyzed "healthy" Google searches ... health-related, e.g., "healthy diet") originating in the U.S. from ...
(Date:4/18/2014)... could lead to potential new treatments for breaking the ... , Fibrosis, or scarring, is a hallmark of the ... can lead to serious organ damage and, in some ... centers on findings made by Swati Bhattacharyya, PhD, research ... a specific protein plays in promoting fibrosis. , ...
(Date:4/17/2014)... in non-cancerous prostate tissue may have nearly twice the ... no inflammation, according to results of a new study ... Center. , The link between persistent inflammation and cancer ... cancer those with a Gleason score between 7 ... aggressive and rapidly growing prostate cancers. , "What we,ve ...
Breaking Medicine News(10 mins):Health News:Benaroya Research Institute evaluates immunology approach to blocking breast cancer 2Health News:New research shows people are thinking about their health early in the week 2Health News:New clues on tissue scarring in scleroderma 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 3
... Oct. 15 One Heartland will host "S,more to Love", a ... Open House Lofts, NYC to benefit Birch Family Camp. , Celebrating ... (over 200 family members) from the 5 boroughs of NYC, along ... building at a camp facility located in the Hudson Valley. ...
... 15 The Longaberger Company is teaming up with the ... against breast cancer. As part of the "Crucial Catch" campaign ... players - in partnership with the American Cancer Society - ... feature players, coaches and referees wearing pink game apparel to ...
... TALLAHASSEE, Fla. -- A Florida State University College of Medicine ... Institutes of Health (NIH) totaling $2.4 million to continue her ... months. Amy Wetherby is director of the Autism Institute ... WORDS Project has screened children to identify early red flags ...
... to curtail secondhand smoke, experts say , , THURSDAY, Oct. ... really do work at reducing heart attacks from secondhand smoke, ... the risk of heart attack by up to 47 ... according to a report released Thursday by the U.S. Institute ...
... Oct. 15 Astrup Drug Inc. has announced ... (ECRS) point-of-sale retail automation suite in their 11 ... selected by Astrup Drug to seamlessly automate their ... convenience/fuel integration, warehousing, front-end inventory control, and centralized ...
... for Presentation Also Nominated for Prestigious Prize , ... nine abstracts based on research by a total of 15 ... doctors, researchers and psychological social workers will be featured this ... meeting in Atlanta. , (Logo: http://www.newscom.com/cgi-bin/prnh/20090203/DC66439LOGO ...
Cached Medicine News:Health News:One Heartland Hosting: S'more to Love Cocktail Fundraiser 2Health News:FSU researcher wins $2.4M in grants to pursue early detection of autism 2Health News:FSU researcher wins $2.4M in grants to pursue early detection of autism 3Health News:Smoking Bans Reduce Heart Attacks: Study 2Health News:Smoking Bans Reduce Heart Attacks: Study 3Health News:Astrup Drug Implements ECRS Retail Solution Suite to Address Diverse Business Requirements 2Health News:Shady Grove Fertility Center Research to Be Showcased at Premier Annual Medical Conference on Reproductive Medicine 2Health News:Shady Grove Fertility Center Research to Be Showcased at Premier Annual Medical Conference on Reproductive Medicine 3Health News:Shady Grove Fertility Center Research to Be Showcased at Premier Annual Medical Conference on Reproductive Medicine 4
Softsplint after bunion surgery. Hook-and-loop closure. Maintains hallux positioning and metatarsophalangeal alignment. Washable....
... The Pediatric Ankle Cryo/Cuff is specifically designed ... 7). Using a combination of controlled compression ... and pain. The Pediatric Ankle Cryo/Cuff is ... hemorrhagic episodes in hemophilia.,The Pediatric Ankle Cryo/Cuff ...
... Air-Stirrup Plus combines the clinically proven ... wrap. In addition, a comprehensive instruction ... Plus and provides information on treatment ... ankle sprain management.,Each Air-Stirrup Ankle Brace ...
... Full Transportability: Innovative design allows ... plug in for therapy or when ... Controller: Choose the prophylactic method to ... or both simultaneously. ,Automatic Garment Detection: ...
Medicine Products: